Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains ...

A few days ago, the European Medicines Agency approved a new drug to delay or slow down the progression of Alzheimer's ...

Biogen expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the United States ...

The drugs aducanumab (Aduhelm), lecanemab (Leqembi), and donanemab (Kisunla) work to reduce the buildup of plaques in the ...

Medicare Part B covers Leqembi for people with early Alzheimer's or mild cognitive impairment. Learn more about Leqembi and Medicare coverage here.

For spouses who care for a partner with Alzheimer’s disease, every day brings a different battle and a new challenge. Every ...

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced that the Federal Commission for the Protection Against Sanitary Risk ...

TOKYO and CAMBRIDGE, Mass., Dec. 4, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate ...

STOCKHOLM, Dec. 4, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) ...

Biogen faces potential earnings drop of 20-30% by 2030 due to Ocrevus biosimilar competition. Leqembi (lecanemab) sales growth remains sluggish, falling below consensus projections through 2030.

Dec 3 (Reuters) - Biogen (BIIB.O), opens new tab expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the United States in the near term, a company ...